Literature DB >> 2037669

Development of natural immunity in Plasmodium falciparum malaria: study of antibody response by Western immunoblotting.

J Thelu1, I Sheick-Zakiuddin, C Boudin, F Peyron, S Picot, P Ambroise-Thomas.   

Abstract

A longitudinal study was carried out in Burkina Faso to investigate the natural development of the immune response to Plasmodium falciparum malaria. Three bleedings were carried out before, during, and after the seasonal peak of transmission. Detailed antigen mapping and antibody prevalence of the 248 collected serum samples were established by immunoblotting on the basis of several epidemiological and biological parameters. An improved Western immunoblotting system was used to analyze up to 67 serum samples on each nitrocellulose sheet. This system allowed us to perform the entire study with strictly comparable conditions. Two different blood-stage antigens (exoantigens and somatic antigens) were used to analyze the distribution of different classes and subclasses of immunoglobulins according to the age of the individuals, the presence or absence of a malarial attack, the transmission period, the origin of parasite isolates, and the response to intraerythrocytic stages. Although this analysis emphasizes strong individual variations, reactions with two major antigens of 115 and 103 kDa were especially noted. These antigens induced high antibody levels and prevalences but were probably not involved in protection. The prevalence of immunoglobulin G (IgG) antibodies differed by isotype. Most of antigens stimulating IgG production were also responsible for the IgM antibody response. The role played by these antibodies in the development of natural immunity against malaria is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037669      PMCID: PMC269810          DOI: 10.1128/jcm.29.3.510-518.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  Plasmodium-specific immunoglobulin E in sera from an area of holoendemic malaria.

Authors:  R S Desowitz
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Jul-Aug       Impact factor: 2.184

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins.

Authors:  C R Merril; D Goldman; S A Sedman; M H Ebert
Journal:  Science       Date:  1981-03-27       Impact factor: 47.728

4.  A high molecular weight antigen in Plasmodium falciparum recognized by inhibitory monoclonal antibodies.

Authors:  A Saul; P Myler; L Schofield; C Kidson
Journal:  Parasite Immunol       Date:  1984-01       Impact factor: 2.280

5.  Antigenic diversity in the human malaria parasite Plasmodium falciparum.

Authors:  J S McBride; D Walliker; G Morgan
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

6.  Characterization of antigens from erythrocytic stages of Plasmodium falciparum reacting with human immune sera.

Authors:  L H Perrin; R Dayal; H Rieder
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

7.  Synchronization of Plasmodium falciparum erythrocytic stages in culture.

Authors:  C Lambros; J P Vanderberg
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

8.  Stage-specific proteins and glycoproteins of plasmodium falciparum: identification of antigens unique to schizonts and merozoites.

Authors:  A Kilejian
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

9.  Stage-specific production of S-antigens of Plasmodium falciparum in vitro.

Authors:  E J Winchell; I T Ling; R J Wilson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

10.  Surface antigens of malaria merozoites. A high molecular weight precursor is processed to an 83,000 mol wt form expressed on the surface of Plasmodium falciparum merozoites.

Authors:  R R Freeman; A A Holder
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  6 in total

1.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

2.  Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin.

Authors:  I G Azcárate; P Marín-García; N Camacho; S Pérez-Benavente; A Puyet; A Diez; L Ribas de Pouplana; J M Bautista
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Plasmodium falciparum-specific immunoglobulin G (IgG), IgM, and IgE antibodies in paired maternal-cord sera from east Sepik Province, Papua New Guinea.

Authors:  R S Desowitz; J Elm; M P Alpers
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

4.  Antibody response in Plasmodium vinckei malaria after treatment with chloroquine and adjuvant interferon-gamma.

Authors:  S Finnemann; P G Kremsner; M F Chaves; C Schumacher; S Neifer; U Bienzle
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

5.  Malaria diagnosis: identification of an anti-40-kDa polypeptide antibody response associated with active or recent infection and study of the IgG/IgM ratio of antibodies to blood-stage Plasmodium falciparum antigens.

Authors:  H C Balthazar-Guedes; M F Ferreira-Da-Cruz; S Montenegro-James; C T Daniel-Ribeiro
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

6.  Visiting sick people: is it really detrimental to our health?

Authors:  David Fouchet; John O'Brien; Dominique Pontier
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.